Amniostat-FLM: an initial clinical trial with both vaginal pool and amniocentesis samples.
Amniostat-FLM, a new rapid slide agglutination test, was compared with thin-layer chromatography as a method for detecting phosphatidylglycerol in amniotic fluid. This is the first reported use of Amniostat-FLM to evaluate vaginal pool and contaminated vaginal pool amniotic fluid. One hundred one of 161 amniotic fluid samples were collected from the vaginal pool. Thirty-nine of these were contaminated. Vaginal pool amniotic fluid, whether contaminated or not, did not adversely effect the ease of performance, reliability, or interpretation of Amniostat-FLM. This test seems ideally suited to institutions where 24-hour availability of thin-layer chromatography is not available. In institutions where it is available, Amniostat-FLM could be used as a screening test. Amniostat-FLM was found to be significantly less sensitive when compared with thin-layer chromatography in detecting the presence of phosphatidylglycerol. At our institution the screening of amniotic fluid samples with Amniostat-FLM before use of thin-layer chromatography was only cost effective at greater than or equal to 34 weeks of gestation.
D000372:Agglutination Tests; D000649:Amniocentesis; D000653:Amniotic Fluid / Q000378:metabolism*; D002855:Chromatography, Thin Layer; D002986:Clinical Trials as Topic; D003365:Costs and Cost Analysis; D005189:False Positive Reactions; D005260:Female; D005325:Fetal Organ Maturity; D006801:Humans; D007231:Infant, Newborn; D008168:Lung / Q000196:embryology*; D010715:Phosphatidylglycerols / Q000032:analysis*; D011247:Pregnancy; D011263:Pregnancy Trimester, Third; D011933:Reagent Kits, Diagnostic / Q000191:economics; D012127:Respiratory Distress Syndrome, Newborn / Q000175:diagnosis; D014621:Vagina / Q000378:metabolism*
D010715:Phosphatidylglycerols; D011933:Reagent Kits, Diagnostic